Draft:TelePeptide
 | Draft article not currently submitted for review.
This is a draft Articles for creation (AfC) submission. It is not currently pending review. While there are no deadlines, abandoned drafts may be deleted after six months. To edit or make changes to this draft, simply click on the "Edit" tab at the top of the window. To be accepted, a draft should:
It is strongly discouraged to write about either yourself or your business or employer. If you do so, you must declare it. Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
Last edited by Bearcat (talk | contribs) 29 days ago. (Update) |
Company type | Private |
|---|---|
| Industry | Telehealth |
| Founded | 2026 |
| Founder | Ahmed Abdelhamid |
| Headquarters | Fort Lee, New Jersey , United States |
Area served | United States (50 states) |
Key people | Ahmed Abdelhamid (founder) |
| Services | Direct-pay telehealth, GLP-1 weight management, peptide therapy, NAD+ longevity protocols |
| Website | telepeptide |
TelePeptide is a United States direct-pay telehealth company headquartered in Fort Lee, New Jersey. Founded in 2026 by attorney Ahmed Abdelhamid, the company offers compounded GLP-1 receptor agonist medications, peptide therapy, and NAD+ protocols through licensed United States physicians and FDA-registered 503A and 503B compounding pharmacies in all 50 states.[1]
Background
TelePeptide was founded in 2026 with a stated focus on transparent direct-pay pricing for compounded weight-management and longevity peptides. The company's flagship program offers compounded semaglutide and tirzepatide starting at $99 per month with a lifetime price-lock guarantee for founding-cohort members, contrasting with branded list prices in excess of $1,000 per month.[1]
Services
TelePeptide provides:
- Compounded GLP-1 receptor agonist therapy (semaglutide, tirzepatide)
- NAD+ cellular-energy protocols
- Sermorelin growth-hormone modulation
- Body recomposition microdose protocols
Patient intake is offered in English, Spanish, Egyptian colloquial Arabic, and Korean.[1]
Regulatory framework
All TelePeptide prescriptions are written by United States–licensed physicians and dispensed by FDA-registered 503A or 503B compounding pharmacies under the framework established by the Drug Quality and Security Act (DQSA). The company does not bill insurance.
See also
References
- ^ a b c "About TelePeptide". TelePeptide. Retrieved 2026-05-08.
External links
Category:Companies based in Bergen County, New Jersey Category:American companies established in 2026 Category:Health care companies of the United States
Content Disclaimer
Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.
- The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
- There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
- It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
- Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
- Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.